White Peak Distillery (WPD) is a whisky distillery that aims to change the way whisky is made and create authentic flavours. It has so far invested £1.4 million in tried and tested plant equipment producing 400,000 bottles of maturing whisky. The company aims to become a contender in the $60 billion global premium whisky market. WPD has received 'Gold Awards' from The Wizards of Whisky World Whisky Awards. It has come out with programs to monetise its maturing whisky including its Cask Sales program, Temperance Club membership and its Prologue 2.1 release 2-year aged single malt spirit, that has been received with positive feedback. WPD has also been awarded visitor business in The Peak District, which receives 13 million+ visitors per annum, boosting its Direct-to-Consumer (D2C) model. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,301,320
The Green Light Change (GLC) team provides a software-as-a-service (SaaS) platform known as 'Insight'. Insight is a new way to deliver projects that are proven to bring up the corporate margins in less than four months. The Insight platform has been adopted by customers, such as, Ramboll Group A/S who has received astonishingly rapid results. The team of Greenlight Change has years of experience in delivering and producing successful software products and complex project portfolios. The company has two revenue models, namely, SaaS Annuity Stream and Professional Services. Furthermore, it should have a minimum raise of £220k for a cash runway of 7 to 9 months and a raise of £440k for a cash runway of 12 to 15 months.
days to go:
Expired
investment:
£25,064
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
Percuro is a low carbon, next-generation pet food that is ethically farmed and formulated using insect proteins. The company argues that its pet food has a low carbon pawprint whilst being hypoallergenic and nutritious with low inflammation properties. Percuro has launched its Direct-To-Consumer (DTC) site in the UK and Germany with a roll-out plan that includes covering additional EU markets later in 2021, raised a £340,000 seed investment in the previous 10 months, and signed product listing agreements with key retailers in the UK and Singapore. The company will use 40% of the investment for brand building through digital marketing, 30% for retailer brand-building investments, 20% towards launching treats and its plant dog range, and 10% towards new market expansion into Asia.
days to go:
Expired
investment:
£618,596
WebTicketManager Limited or WTM has made an online software platform which helps the customers by providing information on attractions and events, with a complete ticketing solution. The company has customers including The Beatles Story museum and stadium tours at Twickenham and Chelsea FC and has over 250 other users. The company will use the funds for developing capital for marketing.
days to go:
Expired
investment:
Withheld
Wise Analytics Group uses data to help companies, consumers and brands make better connections and more benefitial choices. They are a leader in terms of media analytics in the beauty sector, using a range of tools, technology and experience to create a product, market and consumer insight. Wise Analytics group have clients such as L'Oreal and Estee lauder. They are now looking to expand into other locations.
days to go:
Expired
investment:
Withheld
TiPJAR is a global cashless tipping platform that allows users to tip hospitality staff, buskers and hairdressers using 'Open Banking'. The company points out that tipped workers are earning less each year as cash transactions reduce, with Covid-19 having furthered this problem. It claims to have a powerful distribution engine empowering staff to control and share tips fairly and transparently. TiPJAR argues that its portal has been approved by Her Majesty's Revenue and Customs (HMRC) as an alternative to the traditional tronc system. The company asserts that its app is already live in over 1650 venues, with over 100,000 users using the platform. The company aspires to dominate the estimated global tipping market worth a combined $100 billion per year. TiPJAR stresses that it is also the world’s first multi-currency, scalable solution that works in multiple countries. They state they will use the investment received to prepare the business for rapid scale-up growth.
days to go:
Expired
investment:
£1,346,659
Juno is a smartphone app for both Android and IOS that aims to connect Betters and Tipsters with each other. Tipsters will be able to go on the app and share useful tips and knowledge that will aid betters in the decision making of their bets.
days to go:
Expired
investment:
£69,090
Ocular Intelligence aim to be at the forefront of exciting markets such as artificial intelligence (AI) and machine vision. They aim to expand the technology to more than facial recognition such as recognising clothing, cars and buildings among many other object types.
days to go:
Expired
investment:
£210,150
Novai is a UK biotechnology company, developing and commercialising transformational technology in ophthalmology. The company's initial focus is on ophthalmic disorders such as glaucoma and AMD (Age-related Macular Degeneration). Novai argues that current clinical endpoints lack early disease biomarkers to objectively detect and measure cell health and response to treatment in the retina. Novai asserts that its proprietary biological marker, DARC (Detection of Apoptosis in Retinal Cells), combined with its bespoke and patented Artificial Intelligence (AI) aided algorithm, allows, for the first time in vivo, identification of cellular-level disease activity in the retina. Novai stresses that DARC can also predict disease progression, allowing for enrichment of clinical trial cohorts. The company anticipates an exit via licensing of its biomarker business to a Contract Research Organisation (CRO), an Initial Public Offering (IPO) following a successful phase 3 trial of the diagnostic platform, or trade sale to a strategic pharmaceutical company.
days to go:
Expired
investment:
£1,314,967
